阿扎那韦硫酸盐

5至<15公斤

每天一次200毫克（4包）

每天80毫克

15至<25公斤

每天一次250毫克（5包）

每天80毫克

≥25公斤且不能吞服胶囊

每天一次300毫克（6包）

每天一次100毫克

<15公斤

不推荐胶囊

15至<20公斤

每天一次150毫克

每天一次100毫克

20至<40公斤

每天一次200毫克

每天一次100毫克

≥40公斤

每天一次300毫克

每天一次100毫克

阿巴卡韦

No in vitro evidence of antagonistic antiretroviral effects with atazanavir ¹

对乙酰氨基酚

Pharmacokinetic interactions unlikely ^{1 238}

阿夫唑嗪

Possible increased alfuzosin concentrations; may result in hypotension ^{1 238 239}

Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

抗酸剂

Possible decreased atazanavir concentrations ^{1 238}

Administer ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir at least 2 hours before or 1–2 hours after antacids ^{1 200 238}

Antiarrhythmic agents (amiodarone, disopyramide, dofetilide, dronedarone, flecainide, systemic lidocaine, mexiletine, propafenone, quinidine)

Amiodarone, dofetilide, dronedarone, flecainide, systemic lidocaine, propafenone, quinidine: Possible increased antiarrhythmic agent concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir; potential for serious and/or life-threatening effects ^{1 200 238 239}

Disopyramide, mexiletine: Possible increased antiarrhythmic agent concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Disopyramide, dofetilide, flecainide, systemic lidocaine, mexiletine, propafenone, quinidine: Use concomitantly with caution; monitor serum concentrations of antiarrhythmic agent ^{1 200 238 239}

Amiodarone: Experts state monitor for amiodarone toxicity if used with ritonavir-boosted or cobicistat-boosted atazanavir; ²⁰⁰ consider monitoring ECG and amiodarone concentrations ²⁰⁰

Dronedarone: Concomitant use with cobicistat-boosted atazanavir contraindicated; ^{238 239} experts state concomitant use with ritonavir-boosted or unboosted atazanavir also contraindicated ²⁰⁰

Anticoagulants, oral (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin)

Apixaban: Increased apixaban concentrations expected ^{200 238}

Dabigatran: Possible increased dabigatran concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{200 238}

Edoxaban: Increased edoxaban concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ²⁰⁰

Rivaroxaban: Possible increased rivaroxaban concentrations; may increase bleeding risk ^{200 238 239}

Warfarin: Potential for increased or decreased warfarin concentrations and serious and/or life-threatening bleeding episodes if used with ritonavir-boosted or unboosted atazanavir; ^{1 200} effect of cobicistat-boosted atazanavir on warfarin concentrations unknown ^{200 238 239}

Apixaban, edoxaban, rivaroxaban: Avoid concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{200 238 239}

Dabigatran: Concomitant use with ritonavir-boosted or cobicistat-boosted atazanavir not recommended in certain patients with renal impairment; ^{200 238} experts state avoid concomitant use in those with Cl _cr <50 mL/minute ²⁰⁰

Warfarin: Monitor INR if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 200 238 239} (especially when initiating or discontinuing atazanavir) and adjust warfarin dosage accordingly; ²⁰⁰ if ritonavir-boosted atazanavir switched to cobicistat-boosted atazanavir, effect on warfarin concentrations not expected to be equivalent ²⁰⁰

Anticonvulsants (carbamazepine, eslicarbazepine, ethosuximide, lamotrigine, oxcarbazepine, phenobarbital, phenytoin)

Carbamazepine: Possible decreased atazanavir concentrations and increased carbamazepine concentrations if used with ritonavir-boosted atazanavir; ^{1 200} possible decreased atazanavir and cobicistat concentrations if used with cobicistat-boosted atazanavir; ^{238 239} decreased atazanavir concentrations if used with unboosted atazanavir ^{1 200}

Eslicarbazepine: Possible decreased atazanavir and cobicistat concentrations if used with cobicistat-boosted atazanavir ²³⁸

Ethosuximide: Possible increased ethosuximide concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Lamotrigine: Decreased lamotrigine concentrations and AUC if used with ritonavir-boosted atazanavir; ^{1 200} effect of cobicistat-boosted atazanavir on lamotrigine concentrations unknown; ^{200 238} interaction not expected with unboosted atazanavir ^{1 200}

Oxcarbazepine: Possible decreased atazanavir and cobicistat concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Phenobarbital, phenytoin: Possible decreased concentrations of atazanavir and the anticonvulsant if used with ritonavir-boosted atazanavir; ^{1 200} possible decreased atazanavir and cobicistat concentrations may result in loss of therapeutic effect and development of resistance if used with cobicistat-boosted atazanavir; ^{238 239} decreased atazanavir concentrations if used with unboosted atazanavir ^{1 200}

Carbamazepine: Concomitant use with unboosted atazanavir not recommended; ^{1 200} consider alternative anticonvulsant in patients receiving ritonavir-boosted atazanavir; ²⁰⁰ if used with ritonavir-boosted atazanavir, consider that reduced anticonvulsant dosage may be needed, monitor serum concentrations of both drugs, assess virologic response; ^{200 238 239} concomitant use with cobicistat-boosted atazanavir contraindicated ^{200 238}

Eslicarbazepine: Consider alternative anticonvulsant or alternative antiretroviral; ²³⁸ if used concomitantly with cobicistat-boosted atazanavir, monitor for lack or loss of antiretroviral response ²³⁸

Ethosuximide: Monitor for ethosuximide toxicities if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Lamotrigine: Increased lamotrigine dosage may be needed and consider monitoring lamotrigine concentrations if used with ritonavir-boosted atazanavir or consider alternative anticonvulsant; ^{1 200} monitor lamotrigine concentrations if used with cobicistat-boosted atazanavir or consider alternative anticonvulsant; ^{200 238} dosage adjustments not needed if used with unboosted atazanavir ^{1 200}

Oxcarbazepine: Consider alternative anticonvulsant or alternative antiretroviral; ^{238 239} if used concomitantly with cobicistat-boosted atazanavir, monitor for lack or loss of antiretroviral response ^{238 239}

Phenobarbital, phenytoin: Concomitant use with unboosted atazanavir not recommended; ^{1 200} consider alternative anticonvulsants in patients receiving ritonavir-boosted atazanavir; ²⁰⁰ if used with ritonavir-boosted atazanavir, consider that anticonvulsant dosage adjustment may be needed, monitor serum concentrations of both drugs, and assess virologic response; ²⁰⁰ concomitant use with cobicistat-boosted atazanavir contraindicated ^{200 238}

抗真菌剂，唑类

Fluconazole: No clinically important pharmacokinetic interactions with ritonavir-boosted or cobicistat-boosted atazanavir ^{1 238}

Isavuconazonium (prodrug of isavuconazole): Possible increased isavuconazole concentrations and altered atazanavir concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Itraconazole: Possible increased itraconazole, atazanavir, and cobicistat concentrations if used with ritonavir-boosted , cobicistat-boosted, or unboosted atazanavir ^{1 200 238 239}

Ketoconazole: No clinically important pharmacokinetic interactions with unboosted atazanavir; ¹ possible increased ketoconazole, atazanavir, and cobicistat concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{1 238 239}

Posaconazole: Increased atazanavir concentrations if used with ritonavir-boosted or unboosted atazanavir; ^{32 200} possible pharmacokinetic interactions if used with cobicistat-boosted atazanavir ²⁰⁰

Voriconazole: Decreased atazanavir and voriconazole concentrations if used with ritonavir-boosted atazanavir in patients with functional CYP2C19 allele and decreased atazanavir concentrations and increased voriconazole concentrations in those without functional CYP2C19 allele; ^{1 200} effect of cobicistat-boosted atazanavir on voriconazole concentrations unknown; ^{200 238 239} possible altered atazanavir and voriconazole concentrations if used with unboosted atazanavir ^{1 200}

Fluconazole: Dosage adjustments not needed if used with ritonavir-boosted or cobicistat-boosted atazanavir ²⁰⁰

Isavuconazonium: Monitor for atazanavir-associated adverse effects and virologic efficacy if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir; ²⁰⁰ consider monitoring isavuconazole concentrations ²⁰⁰

Itraconazole: Consider monitoring itraconazole concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir and adjust itraconazole dosage accordingly; ²⁰⁰ caution advised if itraconazole dosage >200 mg daily is used with ritonavir-boosted atazanavir; ¹ specific dosage recommendations not available for use with cobicistat-boosted atazanavir; ^{238 239} some experts state itraconazole dosages >200 mg daily not recommended with ritonavir-boosted or cobicistat-boosted atazanavir unless itraconazole concentrations used to guide antifungal dosage ²⁰⁰

Ketoconazole: Caution advised if ketoconazole dosage >200 mg daily used with ritonavir-boosted atazanavir; ¹ specific dosage recommendations not available for use with cobicistat-boosted atazanavir ^{238 239}

Posaconazole: Monitor for atazanavir-associated adverse effects if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{32 200}

Voriconazole: Do not use with ritonavir-boosted or cobicistat-boosted atazanavir unless potential benefits outweigh risks; ^{1 200 238 239} if used with ritonavir-boosted or cobicistat-boosted atazanavir, monitor for voriconazole-associated adverse effects and loss of voriconazole or atazanavir efficacy and consider monitoring voriconazole concentrations and adjusting voriconazole dosage accordingly; ^{1 200} if used with unboosted atazanavir, monitor for toxicities ²⁰⁰

Antimalarial agents

Fixed combination of atovaquone and proguanil (atovaquone/proguanil): Decreased atovaquone and proguanil concentrations if used with ritonavir-boosted atazanavir ²⁰⁰

Atovaquone/proguanil: Consider alternative antimalarial, if possible ²⁰⁰

Antimycobacterials (bedaquiline, rifabutin, rifampin, rifapentine)

Bedaquiline: Possible increased bedaquiline concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir; ²⁰⁰ clinical importance unknown

Rifabutin: Increased concentrations and AUC of rifabutin and its metabolite if used with ritonavir-boosted or unboosted atazanavir; ^{1 200} increased rifabutin concentrations expected if used with cobicistat-boosted atazanavir, but effects on atazanavir and cobicistat concentrations unknown ^{238 239}

Rifampin: Substantially decreased atazanavir concentrations; possible loss of virologic response and development of resistance ^{1 238}

Rifapentine: Possible decreased atazanavir concentrations with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir with loss of antiretroviral effect and development of resistance ^{1 200 238}

Bedaquiline: If potential benefits outweigh risks, use with ritonavir-boosted or cobicistat-boosted atazanavir with caution and monitor for QT _c interval prolongation and liver dysfunction ²⁰⁰

Rifabutin: If used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir, reduce rifabutin dosage to 150 mg once every other day or 3 times weekly; ^{1 200 238 239} some experts suggest rifabutin 150 mg once daily or 300 mg 3 times weekly; ²⁰⁰ monitor for rifabutin-associated adverse effects (eg, neutropenia, uveitis); ^{1 238 239} monitor for antimycobacterial response and consider therapeutic drug monitoring ²⁰⁰

Rifampin: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

Rifapentine: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir not recommended ²⁰⁰

Antineoplastic agents (dasatinib, irinotecan, nilotinib, paclitaxel, vinblastine, vincristine)

Dasatinib, nilotinib: Possible increased antineoplastic concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Irinotecan: Possible interference with metabolism of irinotecan and increased risk of irinotecan toxicity if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 238 239}

Paclitaxel: Possible increased paclitaxel concentrations if used with unboosted atazanavir; ¹ clinically important interactions not expected if used with ritonavir-boosted atazanavir ¹

Vinblastine, vincristine: Possible increased antineoplastic concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Dasatinib, nilotinib: If used with cobicistat-boosted atazanavir, decreased dosage of the antineoplastic may be needed ^{238 239}

Irinotecan: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

Paclitaxel: Caution advised if used with unboosted atazanavir; ¹ concomitant use with cobicistat-boosted atazanavir not recommended ²³⁸

Vinblastine, vincristine: Monitor for adverse hematologic or GI effects if used with cobicistat-boosted atazanavir ²³⁸

Antipsychotics (lurasidone, perphenazine, pimozide, quetiapine, risperidone, thioridazine)

Lurasidone: Possible increased lurasidone concentrations if used with ritonavir-boosted or unboosted atazanavir; ^{1 238} potential for serious and/or life-threatening adverse effects if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{1 238}

Perphenazine, risperidone, thioridazine: Possible increased antipsychotic agent concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{200 238 239}

Pimozide: Potential for serious and/or life-threatening effects (eg, cardiac arrhythmias) if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 238 239}

Quetiapine: Increased quetiapine concentrations expected if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 200 238 239}

Lurasidone: Concomitant use with ritonavir-boosted or cobicistat-boosted atazanavir contraindicated; ^{1 238} experts state do not use concomitantly with unboosted atazanavir; ²⁰⁰ if concomitant use with unboosted atazanavir necessary, reduce lurasidone dosage ¹

Perphenazine, risperidone, thioridazine: Decreased antipsychotic dosage may be needed if used with ritonavir-boosted or cobicistat-boosted atazanavir; ^{200 238 239} experts state initiate antipsychotic at lowest dosage, adjust maintenance dosage as needed, and monitor for antipsychotic-associated toxicities ²⁰⁰

Pimozide: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

Quetiapine: Consider alternative antiretroviral; ^{1 238 239} if ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir necessary in patient receiving stable quetiapine dosage, reduce quetiapine dosage to one-sixth of original dosage and monitor for quetiapine efficacy and adverse effects; ^{1 200 238 239} if quetiapine necessary in patient receiving ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir, experts state initiate using lowest quetiapine dosage and titrate as needed ²⁰⁰

Atovaquone

Ritonavir-boosted atazanavir: No effect on atovaquone concentrations ²⁰⁰

Ritonavir-boosted atazanavir: Dosage adjustments not needed ²⁰⁰

阿瓦那非

Possible increased avanafil concentrations and AUC ^{183 200 238 239}

Do not use concomitantly with ritonavir-boosted or cobicistat-boosted atazanavir; ^{183 200 238 239} experts state that unboosted atazanavir can be used if avanafil dosage does not exceed 50 mg once every 24 hours ²⁰⁰

Benzodiazepines

Alprazolam: Possible increased alprazolam concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Clonazepam: Possible increased clonazepam concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{200 238 239}

Diazepam: Possible increased diazepam concentrations If used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{200 238 239}

Midazolam or triazolam: Possible increased concentrations of midazolam or triazolam and potential for serious and/or life-threatening effects (eg, prolonged or increased sedation or respiratory depression) if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 238 239}

Lorazepam, oxazepam, temazepam: No data, but may have less potential for pharmacokinetic interactions with PIs compared with other benzodiazepines ²⁰⁰

Alprazolam: Consider alternative benzodiazepine with less potential for interactions (eg, lorazepam, oxazepam, temazepam) ²⁰⁰

Clonazepam: Clinical monitoring recommended if used with cobicistat-boosted atazanavir; ^{238 239} experts state consider alternative (eg, lorazepam, oxazepam, temazepam) ²⁰⁰

Diazepam: If used with cobicistat-boosted atazanavir, decreased diazepam dosage may be needed and monitor for adverse effects; ^{238 239} experts state consider alternative (eg, lorazepam, oxazepam, temazepam) ²⁰⁰

Oral midazolam or triazolam: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239</}

已知共有478种药物与阿扎那韦相互作用。

• 201种主要药物的相互作用
• 245种中等程度的药物相互作用
• 32种次要药物相互作用

在数据库中显示可能与阿扎那韦相互作用的所有药物。

检查互动

输入药物名称以检查与atazanavir的相互作用。

最常检查的互动

查看阿扎那韦和下列药物的相互作用报告。

• 乙酰水杨酸（阿司匹林）
• 雄激素（睾丸激素）
• 浓缩钙（碳酸钙）
• Celexa（西酞普兰）
• 铜（葡萄糖酸铜）
• 依法韦仑
• 法莫韦（泛昔洛韦）
• Folinic-Plus（多种维生素）
• K-Phos Original（磷酸钾）
• 拉米夫定
• 镁卡（天门冬氨酸镁）
• 二甲双胍
• 尼莫地平
• 奥美拉唑
• 普拉达沙（达比加群）
• 槲皮素（生物类黄酮）
• 雷格列韦
• 利托那韦
• 思乐康（喹硫平）
• 大豆卵磷脂（卵磷脂）
• 替诺福韦
• Truvada（恩曲他滨/替诺福韦）
• 维生素B2（核黄素）
• 维生素B6（吡rid醇）
• 维生素C（抗坏血酸）
• 维生素D3（胆钙化固醇）
• 维生素K（植物二酮）
• 锌（硫酸锌）

阿扎那韦醇/食物相互作用

阿扎那韦与酒精/食物有3种相互作用

阿扎那韦病毒相互作用

与阿扎那韦有8种疾病相互作用，包括：

• 心脏传导阻滞
• 肾结石症
• 肾功能不全
• 血友病
• 肝病
• 北大
• 高血糖症
• 高脂血症

药物状态

• 可用性 仅处方
• 怀孕和哺乳 现有风险数据
• CSA时间表* 不是管制药物
• 审批历史 FDA的药物史

相关药物

• 特鲁瓦达
• Isentress
• 苏斯蒂瓦
• 完成
• Epzicom
• Emtriva
• Atripla

美国日本医生

Heather Benjamin MD

经验：11-20年

Heather Benjamin MD

经验：11-20年

Suzanne Reitz MD

经验：11-20年

Heather Miske DO

经验：11-20年

Heather Miske DO

经验：11-20年

渡邊剛

经验：21年以上

渡邊剛

经验：21年以上

宮崎総一郎 中部大学特聘教授

经验：21年以上

百村伸一 教授

经验：21年以上

百村伸一 教授

经验：21年以上

临床试验

• Hemay022联合内分泌治疗用于晚期 ER 阳性和 Her2 阳性乳腺癌Ⅲ期临床研究
• MW11注射液治疗乳腺癌临床试验
• GB491联合来曲唑治疗HR+/HER2-乳腺癌的III期临床试验
• AZD9833单药治疗和与哌柏西利或依维莫司联合治疗用于转移性乳腺癌患者
• 注射用A166治疗末线HER2阳性乳腺癌患者的II期临床研究
• GB491联合氟维司群治疗HR+/HER2-乳腺癌的III期临床试验
• 一项评估重组人源化抗HER2单抗-Tub114偶联剂（DX126-262）在HER2阳性不可切除的局部晚期或复发转移性乳腺癌患者中的有效性及安全性的Ⅱ期临床研究
• HRS8807单药及联合SHR6390在晚期乳腺癌患者中的I期研究
• 评估 Capivasertib + 氟维司群对比安慰剂 + 氟维司群治疗局部晚期（不可手术）或转移性乳腺癌的疗效和安全性的研究
• 哌柏西利胶囊在健康受试者中空腹/餐后状态下生物等效性研究。